BRIEF-Aralez announces FDA approval of Yosprala for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin-associated gastric ulcers

Thu Sep 15, 2016 9:40am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Sept 15 (Reuters) - Aralez Pharmaceuticals Inc

* Announces FDA approval of YOSPRALA for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin associated gastric ulcers

* Aralez Pharmaceuticals Inc says YOSPRALA U.S. commercial launch planned for first week of october

* Each study achieved its individual primary endpoint

* Aralez Pharmaceuticals Inc says Aralez sales force will be expanded by 85 to 110 sales representatives by launch

* Says studies demonstrate yosprala clinical benefit Source text for Eikon: Further company coverage: